Interferon beta - TIGO

Drug Profile

Interferon beta - TIGO

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator TIGO
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Alopecia areata

Highest Development Phases

  • Preclinical Alopecia areata

Most Recent Events

  • 20 Jul 2016 Preclinical trials in Alopecia areata in Germany (unspecified route)
  • 20 Jul 2016 Interferon beta - TIGO is available for licensing as of 20 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top